RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Olav Engebraaten(Oslo University Hospital), Anette Weyergang(Oslo University Hospital)
Cited by 1
Related Papers
Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal‐ and luminal‐like breast cancer xenografts
|Molecular Oncology|2012|21
Light-enhanced VEGF121/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment
|Frontiers in Immunology|2023|7